Yuan Chen

Title(s)Professor, Surgery
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Rutgers University, New JerseyPh.D.12/1991Biochemistry
    The Scripps Research Institute, La Jolla, CApost-doctoral training11/1993Structural and Molecular Biology

    Collapse Overview 
    Collapse Overview
    The long-term objective of the Chen laboratory is to identify novel mechanisms that can be targeted for developing innovative treatments for cancer and other recalcitrant human diseases. Their research focus for two decades has been on ubiquitin-like (Ubl) modifications, the regulation of which influences major oncogenic pathways and anti-tumor immunity. Even though more than 1000 enzymes/proteins are involved, Ubl modifications have been poorly addressed by FDA approved drugs, and thus are an untapped resource for new therapeutic development. The Chen laboratory has made major contributions to the discovery of new chemical and biochemical approaches to target Ubl modifications and to the elucidation of small ubiquitin-like modification (SUMO)-mediated cellular regulatory mechanisms. Her research program is transdisciplinary involving collaborations with other academic laboratories, clinicians and biotech industry.
    Collapse Websites

    Collapse Research 
    Collapse Research Activities and Funding
    SUMO Modification and Cancer Therapy
    NIH R01CA265410May 1, 2021 - Apr 30, 2026
    Role: Principal Investigator
    STAT3, G6PD AND TRXR As Underlying Mechanisms For Antitumor Responses To Hirsutinolides
    NIH 1R01CA208851-01A1Dec 1, 2018 - Nov 30, 2023
    Role: Co-I
    A Novel Approach to Eradicate Cancer Stem Cells
    CIRM DISC2-10107Oct 1, 2017 - Oct 30, 2020
    Role: PI
    Targeting c-Myc and Proteasome Inhibitor Resistance in Multiple Myeloma
    NIH R01CA212119Jul 1, 2017 - Jun 30, 2022
    Role: Principal Investigator
    K-Ras Sumoylation in Cell Proliferation and Transformation
    NIH R01 CA216987-01A1Jun 1, 2017 - May 31, 2022
    Role: Multi-PI
    SUMO Modification and Cancer Therapy
    NIH R01 GM086171Apr 1, 2008 - Nov 30, 2021
    Role: PI
    Activating Anti-Tumor Immunity by Targeting a Ubl Modification
    Pancreatic Cancer Action Network
    Role: PI

    Collapse ORNG Applications 
    Collapse Faculty Mentoring

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme. Cell Chem Biol. 2019 02 21; 26(2):278-288.e6. Li YJ, Du L, Wang J, Vega R, Lee TD, Miao Y, Aldana-Masangkay G, Samuels ER, Li B, Ouyang SX, Colayco SA, Bobkova EV, Divlianska DB, Sergienko E, Chung TDY, Fakih M, Chen Y. PMID: 30581133; PMCID: PMC6524651.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    2. Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme. Nat Commun. 2018 12 04; 9(1):5145. Lv Z, Yuan L, Atkison JH, Williams KM, Vega R, Sessions EH, Divlianska DB, Davies C, Chen Y, Olsen SK. PMID: 30514846; PMCID: PMC6279746.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    3. Sumoylation of ROR?t regulates TH17 differentiation and thymocyte development. Nat Commun. 2018 11 19; 9(1):4870. He Z, Zhang J, Huang Z, Du Q, Li N, Zhang Q, Chen Y, Sun Z. PMID: 30451821; PMCID: PMC6242824.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    4. Role of SUMO activating enzyme in cancer stem cell maintenance and self-renewal. Nat Commun. 2016 07 28; 7:12326. Du L, Li YJ, Fakih M, Wiatrek RL, Duldulao M, Chen Z, Chu P, Garcia-Aguilar J, Chen Y. PMID: 27465491; PMCID: PMC4974481.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCells
    5. Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc Natl Acad Sci U S A. 2004 Oct 05; 101(40):14373-8. Song J, Durrin LK, Wilkinson TA, Krontiris TG, Chen Y. PMID: 15388847; PMCID: PMC521952.
      View in: PubMed   Mentions: 282     Fields:    Translation:HumansCells
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    See more options in the Advanced Search tab

    Yuan's Networks
    Concepts (66)
    Derived automatically from this person's publications.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version pre_new_search-4-g7119b7be on PROFILES-PWEB04.

    Copyright © The Regents of the University of California